Travere Therapeutics Inc. (TVTX)
$45.04
$0.28
(0.63%)
As on 07-May-2026 10:40EDT
Market cap
$4,166 Mln
Revenue (TTM)
$491 Mln
P/E Ratio
--
P/B Ratio
36.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
183.7
-
Debt to Equity
2.9
-
Book Value
$1.3
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
92,369,812
10 Years Aggregate
CFO
$-647.62 Mln
EBITDA
$-1,038.47 Mln
Net Profit
$-1,089.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Travere Therapeutics (TVTX)
| 17.9 | 41.5 | 52.8 | 125.8 | 38.9 | 13.9 | 11.9 |
|
BSE Sensex
| -8.1 | 5.0 | -6.9 | -3.5 | 8.4 | 9.7 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Travere Therapeutics (TVTX)
| 119.3 | 92.7 | -57.3 | -32.2 | 13.9 | 91.9 | -37.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Travere Therapeutics (TVTX)
|
45.0 | 4,166.1 | 490.7 | -50.3 | -7.9 | -57.8 | -- | 36.2 |
| 77.6 | 10,492.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.8 | |
| 232.4 | 13,917.7 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 46.7 | 11,283.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16 | 5.2 | |
| 90.5 | 11,868.0 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 286.6 | 8,389.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38 | 6.6 | |
| 521.5 | 11,584.7 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 428.1 | 12,289.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.1 | 19.9 | |
| 102.2 | 8,013.9 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 332.6 | 9,289.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Travere Therapeutics (TVTX)
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily,... oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California. Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130 Read more
-
President, CEO & Director
Dr. Eric M. Dube Ph.D.
-
President, CEO & Director
Dr. Eric M. Dube Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Travere Therapeutics (TVTX)
What is the current share price of Travere Therapeutics Inc (TVTX) Today?
The share price of Travere Therapeutics Inc (TVTX) is $45.04 (NASDAQ) as of 07-May-2026 10:40 EDT. Travere Therapeutics Inc (TVTX) has given a return of 38.92% in the last 3 years.
What is the current PB & PE ratio of Travere Therapeutics Inc (TVTX)?
Since, TTM earnings of Travere Therapeutics Inc (TVTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-67.66
|
29.62
|
|
2024
|
-4.28
|
23.29
|
|
2023
|
-5.97
|
3.31
|
|
2022
|
-4.83
|
31.41
|
|
2021
|
-10.34
|
6.16
|
What is the 52 Week High and Low of Travere Therapeutics Inc (TVTX)?
The 52-week high and low of Travere Therapeutics Inc (TVTX) are Rs 48.60 and Rs 13.88 as of 07-May-2026.
What is the market cap of Travere Therapeutics Inc (TVTX)?
Travere Therapeutics Inc (TVTX) has a market capitalisation of $ 4,166 Mln as on 06-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Travere Therapeutics Inc (TVTX)?
Before investing in Travere Therapeutics Inc (TVTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.